AngioDynamics (NASDAQ:ANGO) Issues Earnings Results

Key Points

• AngioDynamics exceeded quarterly expectations: Revenue rose 6.9% year over year to $80.9 million, while adjusted EPS of $(0.04) beat the $(0.11) consensus estimate. The GAAP net loss narrowed to $7.1 million from $10.9 million.
• Medical technology growth and margins improved: Med Tech sales increased 13.2%, driven by Auryon and NanoKnife, while gross margin expanded 410 basis points to 59.4%. The company also received FDA approval for a NanoKnife feasibility study in benign prostatic hyperplasia.
• Risks remain despite a generally positive outlook: Fiscal 2027 guidance was maintained, but the company remains unprofitable, used $15.3 million in operating cash during the quarter, and held $34.0 million in cash. Shares fell 1.6%, while an insider sold approximately $344,000 of stock.

AngioDynamics (NASDAQ:ANGO - Get Free Report) issued its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07, FiscalAI reports. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics updated its FY 2027 guidance to -0.290--0.240 EPS.

AngioDynamics Stock Down 1.6%

Shares of ANGO opened at $14.19 on Thursday. The business's 50 day moving average price is $15.46 and its 200-day moving average price is $13.11. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29. The stock has a market cap of $596.69 million, a P/E ratio of -16.31 and a beta of 0.30.

AngioDynamics News Roundup

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Quarterly results exceeded expectations: AngioDynamics reported revenue of $80.9 million, above the $80.5 million consensus estimate, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, and the GAAP net loss narrowed to $7.1 million from $10.9 million. AngioDynamics Fiscal 2027 First-Quarter Financial Results
• Positive Sentiment: Medical technology growth was strong: Med Tech sales rose 13.2% to $39.9 million, led by Auryon sales growth of 14.7% and NanoKnife sales growth of 29.0%. Gross margin also expanded 410 basis points to 59.4%, indicating improved operating performance.
• Positive Sentiment: Pipeline and leadership developments may support the outlook: The FDA approved an IDE for a NanoKnife feasibility study in benign prostatic hyperplasia, while Eric Honroth is set to become president and CEO on November 2, 2026. CEO Appointment
• Neutral Sentiment: Full-year guidance was reiterated: Fiscal 2027 revenue is expected at $336 million to $341 million, slightly above the $337.6 million analyst consensus at the midpoint. EPS guidance of $(0.29) to $(0.24) is broadly in line with the $(0.26) consensus estimate.
• Negative Sentiment: Profitability and liquidity remain risks: The company still reported a GAAP loss, negative net margin and negative return on equity. It used $15.3 million in operating cash during the quarter, leaving $34.0 million in cash at August 31.
• Negative Sentiment: Insider selling may temper sentiment: A senior vice president sold 23,370 shares for approximately $344,000, with no reported insider purchases during the past six months.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the firm's stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.00% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of AngioDynamics in a report on Friday, July 17th. Canaccord Genuity Group lifted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Zacks Research raised AngioDynamics from a "strong sell" rating to a "hold" rating in a research note on Monday. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a report on Saturday, August 22nd. Finally, HC Wainwright raised their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, AngioDynamics currently has an average rating of "Moderate Buy" and an average target price of $19.50.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company's portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.